ArticleIn vivo (Athens, Greece)
Ifosfamide, Carboplatin, and Etoposide as Neoadjuvant Chemotherapy in Patients With Neurofibromatosis Type I-related Malignant Peripheral Nerve Sheath Tumors.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe role of chemotherapy for malignant peripheral nerve sheath tumors (MPNSTs) remains controversial, particularly in neurofibromatosis type 1 (NF1)-related MPNST (NF1-MPNST). This study aimed to assess the clinical outcomes of patients with NF1-MPNST who underwent curative treatment comprising neoadjuvant chemotherapy followed by wide resection. PATIENTS AND
methodsWe retrospectively analyzed data from patients with NF1-MPNST who received preoperative chemotherapy. The regimen was ifosfamide 1.5 g/m
resultsWe analyzed data from 12 patients treated between 2005 and 2023. All patients received two to four courses of ICE without concomitant radiation therapy, with a median 20.4% (range=-14-63%) reduction in tumor size. According to the RECIST criteria, four patients had partial responses and eight had stable disease. The 5-year overall survival rate was 81.8%. The survival rate of patients with a partial response was 100%. Toxicities included myelosuppression, nausea, and general fatigue. Three patients received platelet transfusions. Three patients discontinued neoadjuvant chemotherapy because of patient preference.
conclusionIn this study, we achieved more favorable outcomes than those in previous studies. Neoadjuvant chemotherapy, which included the ICE regimen, not only resulted in tumor shrinkage in eight of 12 cases but also demonstrated a good prognosis when tumor shrinkage was achieved. These findings suggest that neoadjuvant chemotherapy with the ICE regimen may be a promising approach for managing NF1-MPNST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.